GenMark surges following Roche acquisition announcement Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- GenMark (GNMK) up 28% after Roche (RHHBY) and the company announced that they have entered into a definitive merger agreement for Roche to fully acquire GenMark at a price of $24.05 per share in an all-cash transaction
- BioXcel Therapeutics (BTAI) up 8% after announcing that BXCL501 has been granted breakthrough therapy designation from the FDA for the acute treatment of agitation associated with dementia
- AMC Theatres (AMC) up 9% after announcing that two of its locations in Los Angeles, AMC Burbank 16 and AMC Century City 15, will reopen this afternoon with plans to open all its remaining 23 movie theatres in Los Angeles County beginning on March 19
- U.S. Steel (X) up 1% after revising its Q1 EPS guidance higher
- Penn National (PENN), Generac (GNRC) and Caesars (CZR) up 6%, 3% and 3%, respectively, after the companies were informed they will all move to the S&P 500 on March 22
- Rubius (RUBY) up 4% after announcing initial clinical, pharmacodynamic and tumor trafficking data from its ongoing Phase 1/2 clinical trial of RTX-240 in patients with advanced solid tumors
UP AFTER EARNINGS -
DOWN AFTER EARNINGS -
- Sesen Bio (SESN) down 4%
- Accel Entertainment (ACEL) down 1%
LOWER -
- DraftKings (DKNG) down 3% after announcing offering of $1B of Convertible Senior Notes due 2028
- Eli Lilly (LLY) down 6% after reporting Phase 2 TRAILBLAZER-ALZ study results
- ViacomCBS (VIAC) down 2% after BMO Capital analyst Daniel Salmon downgraded shares to Underperform from Market Perform with a price target of $70, up from $60
Symbols:
BTAI AMC - $11.13 /
+0.8601 (+8.37%)
X GNMK PENN GNRC CZR DM SESN ACEL DKNG LLY RUBY VIAC VIACA RHHBY Keywords: Fly Intel, Wall Street, Top Stories, Stocks